Winston Pharmaceuticals Ltd.

Win the Fight against Tough Resistant Infections with the Broad Spectrum

Salcy Ceftriaxone 1000 mg + Sulbactam 500 mg Injection

Ceftawin-T Ceftazidime 1000 mg + Tazobactam 125 mg Injection

Powerful Combination to conquer Bacterial Resistance

• Ceftriaxone and Ceftazidime are bactericidal antibiotics, inhibit bacterial cell wall synthesis by binding to one or more penicillin binding proteins (PBPs)
• Sulbactam and Tazobactam are β-lactamase inhibitors act primarily by irreversible inactivation of β-lactamases

Indications:

• Respiratory Tract Infections
• Acute Bacterial Otitis Media
• Sepsis
• Meningitis
• Nosocomial Infections
• Pre & Post operative Surgical Prophylaxis
• Intra-abdominal Infections
• Pelvic Inflammatory Disease
• Infections of Bones, Joint, Skin & Soft Tissue and Wounds
• Renal & Urniary Tract Infections
• Sexually Transmitted Diseases

Benefits:

• Combination of Coverage, Efficacy & Safety offer Increased Success Rate
• Broad Spectrum Antibacterial activity
• Least chances of Resistance
• Superior efficacy than Ceftriaxone alone
• Readily diffuses to most body fluids without harmful effects on brain and spinal fluid.
• Enhanced bioavailability with proven safety even in children and elderly

Dose:

• Adults: Salcy 1 to 2g OD or BID given 12 hourly. Max 4g/day Ceftawin-T 1000/125 mg OD or BID given 12 hourly. Max 4g/day
• Paediatric Patients: Salcy 1 or Ceftawin-T For skin & soft tissue infections: 50 to 75 mg/kg OD or BID given 12 hourly. Max 1g/day For acute bacterial otitis media: 50 mg/kg iv/im. Max 1g/day
• Salcy 1 or Ceftawin-T Meningitis: 100 mg/kg iv/im. Max 4g/day